Frontlight ResearchEarly access
Active, not recruitingNo phase
BioGlue as an Adjunct for Structural Repair and Hemostasis in Chinese Acute Type A Aortic Dissections Patients
Key facts
- Who runs it
- CryoLife, Inc.
- Where
- China7 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 202 people enrolled
- Started
- 1 Nov 2017
- Ended
- Nov 2020
- Type of study
- Interventional, 2 groups
- Treatments tested
- BioGlue Surgical Adhesive
- Traditional Surgical Repair
- Record updated
- 19 May 2020
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Male or female subjects 18-70 years of age
- Subject has a confirmed diagnosis of acute type A aortic dissection with subtype A2
- Subject is willing and able to give written consent for the trial. If the subject is unconscious or under the influence of medications which render him or her unable to give fully informed consent, a guardian may provide informed consent for the subject regarding trial participation
Who cannot take part
- Subjects who have been treated with an investigational product who have not completed the entire follow-up period
- Subjects who do not meet the eligibility criteria, including those who do not wish to participate or give informed consent for trial participation, will not be enrolled into the trial, and will be offered equivalent, non-trial surgical or other treatment, as judged appropriate by the investigator
- Subjects with previous cardiac and aortic surgery
- Previous chronic dissections resulting from non-cardiac surgery and/or trauma
- Concomitant surgery of valve replacement (both in screening and intraoperative)
- End stage malperfusion syndromes (i.e. end-organ failure such as coma, paraplegia, hemiplegia, intestinal necrosis, or hepatic failure)
- Subjects with Marfan syndrome or other connective tissue disorders
- Subjects with known allergy to albumin, bovine products, or glutaraldehyde
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
A multi-center, randomized, controlled clinical trial is designed to investigate the safety and efficacy of BioGlue as an adjunct for structural repair and hemostasis to traditional surgical repair in Chinese subject with Acute type A aortic dissections.
The 2 groups in the trial
- BioGlue Surgical AdhesiveTreatment being tested
Subjects in the BioGlue group will receive BioGlue as an adjunct for traditional surgical repair of the sinus of Valsalva.
- Traditional Surgical RepairOther group
Subjects in the control group will receive traditional surgical repair of the sinus of Valsalva.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Multi-center, Randomized, Controlled Clinical Trial of BioGlue Surgical Adhesive as an Adjunct for Structural Repair and Hemostasis in Chinese Patients With Acute Type A Aortic Dissections.
- Record updated
- 19 May 2020